World Journal of Urology

, Volume 31, Issue 2, pp 359–364 | Cite as

Association of legumain expression pattern with prostate cancer invasiveness and aggressiveness

  • Yoshio Ohno
  • Jun Nakashima
  • Miki Izumi
  • Makoto Ohori
  • Takeshi Hashimoto
  • Masaaki Tachibana
Original Article



To investigate the clinical implication of legumain, an asparaginyl endopeptidase that is highly expressed in several types of cancer, expression in prostate cancer.


Legumain expression in prostate cancer cell lines was determined by real-time reverse transcriptase PCR and Western blot. Furthermore, legumain expression in 88 prostatectomy specimens was evaluated by immunohistochemistry. The association between legumain expression and clinicopathological factors was analyzed.


Legumain expression was confirmed at the mRNA and protein levels in all the cells. Although all the cancer tissues were positive for legumain, 2 staining patterns were observed in the cytoplasm: diffuse cytoplasmic and vesicular positivity. The rates of Gleason score ≥8, extracapsular extension, and perineural invasion in the group with vesicular staining were significantly higher than those in the diffuse cytoplasmic group (p < 0.05). The maximum size of the tumor with vesicular staining was significantly greater than that of the tumor with diffuse cytoplasmic staining (p = 0.0302). The 5-year biochemical recurrence-free rate in the patients with vesicular legumain staining was 53.2 %; this rate was significantly lower than that (78.8 %) in the patients with diffuse cytoplasmic staining (p = 0.0269).


Tumors that showed a vesicular staining pattern of legumain had the potential of being highly invasive and aggressive in patients with prostate cancer who were treated with radical prostatectomy. This suggests that legumain might contribute to the invasiveness and aggressiveness of prostate cancer.


Legumain Prostate cancer Biochemical recurrence Prognostic factor 



This study was partially supported by the Strategic Research-Based Support Project for private universities, with matching funds from the Ministry of Education, Culture, Sports, and Science, Japan.

Conflict of interest

No author has any financial disclosures or conflict of interest to declare.


  1. 1.
    Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRefGoogle Scholar
  2. 2.
    Boorjian SA, Eastham JA, Graefen M et al (2012) A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol 61:664–675PubMedCrossRefGoogle Scholar
  3. 3.
    de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154PubMedCrossRefGoogle Scholar
  4. 4.
    de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005PubMedCrossRefGoogle Scholar
  5. 5.
    Ishii S (1994) Legumain: asparaginyl endopeptidase. Methods Enzymol 244:604–615PubMedCrossRefGoogle Scholar
  6. 6.
    Shirahama-Noda K, Yamamoto A, Sugihara K et al (2003) Biosynthetic processing of cathepsins and lysosomal degradation are abolished in asparaginyl endopeptidase-deficient mice. J Biol Chem 278:33194–33199PubMedCrossRefGoogle Scholar
  7. 7.
    Murthy RV, Arbman G, Gao J et al (2005) Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer. Clin Cancer Res 11:2293–2299PubMedCrossRefGoogle Scholar
  8. 8.
    Gawenda J, Traub F, Luck HJ et al (2007) Legumain expression as a prognostic factor in breast cancer patients. Breast Cancer Res Treat 102:1–6PubMedCrossRefGoogle Scholar
  9. 9.
    Liu C, Sun C, Huang H et al (2003) Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res 63:2957–2964PubMedGoogle Scholar
  10. 10.
    Sobel RE, Sadar MD (2005) Cell lines used in prostate cancer research: a compendium of old and new lines—Part 1. J Urol 173:342–359PubMedCrossRefGoogle Scholar
  11. 11.
    Thalmann GN, Sikes RA, Wu TT et al (2000) LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 44:91–103PubMedCrossRefGoogle Scholar
  12. 12.
    Greene FL, Page DL, Fleming ID (2002) AJCC cancer staging manual, 6th edn. Springer, New YorkGoogle Scholar
  13. 13.
    Mottet N, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59:572–583PubMedCrossRefGoogle Scholar
  14. 14.
    Choi SJ, Reddy SV, Devlin RD et al (1999) Identification of human asparaginyl endopeptidase (legumain) as an inhibitor of osteoclast formation and bone resorption. J Biol Chem 274:27747–27753PubMedCrossRefGoogle Scholar
  15. 15.
    Manoury B, Hewitt EW, Morrice N et al (1998) An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature 396:695–699PubMedCrossRefGoogle Scholar
  16. 16.
    Morita Y, Araki H, Sugimoto T et al (2007) Legumain/asparaginyl endopeptidase controls extracellular matrix remodeling through the degradation of fibronectin in mouse renal proximal tubular cells. FEBS Lett 581:1417–1424PubMedCrossRefGoogle Scholar
  17. 17.
    Choi SJ, Kurihara N, Oba Y et al (2001) Osteoclast inhibitory peptide 2 inhibits osteoclast formation via its C-terminal fragment. J Bone Miner Res 16:1804–1811PubMedCrossRefGoogle Scholar
  18. 18.
    Wang L, Chen S, Zhang M et al (2012) Legumain: a biomarker for diagnosis and prognosis of human ovarian cancer. J Cell Biochem doi: 10.1002/jcb.23143. [Epub ahead of print]
  19. 19.
    Wu W, Luo Y, Sun C et al (2006) Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. Cancer Res 66:970–980PubMedCrossRefGoogle Scholar
  20. 20.
    Stern L, Perry R, Ofek P et al (2009) A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain. Bioconjug Chem 20:500–510PubMedCrossRefGoogle Scholar
  21. 21.
    Bajjuri KM, Liu Y, Liu C et al (2011) The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity. Chem Med Chem 6:54–59PubMedGoogle Scholar
  22. 22.
    Lewen S, Zhou H, Hu HD et al (2008) A legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis. Cancer Immunol Immunother 57:507–515PubMedCrossRefGoogle Scholar
  23. 23.
    Luo Y, Zhou H, Krueger J et al (2006) Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 116:2132–2141PubMedCrossRefGoogle Scholar
  24. 24.
    Lopergolo A, Zaffaroni N (2009) Biomolecular markers of outcome prediction in prostate cancer. Cancer 115:3058–3067PubMedCrossRefGoogle Scholar
  25. 25.
    Darnel AD, Behmoaram E, Vollmer RT et al (2009) Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer. Clin Cancer Res 15:1376–1383PubMedCrossRefGoogle Scholar
  26. 26.
    Miyamoto H, Hernandez DJ, Epstein JI (2009) A pathological reassessment of organ-confined, Gleason score 6 prostatic adenocarcinomas that progress after radical prostatectomy. Hum Pathol 40:1693–1698PubMedCrossRefGoogle Scholar
  27. 27.
    Minner S, Wittmer C, Graefen M et al (2011) High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 71:281–288PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Yoshio Ohno
    • 1
  • Jun Nakashima
    • 1
  • Miki Izumi
    • 2
  • Makoto Ohori
    • 1
  • Takeshi Hashimoto
    • 1
  • Masaaki Tachibana
    • 1
  1. 1.Department of UrologyTokyo Medical UniversityTokyoJapan
  2. 2.Department of Diagnostic PathologyTokyo Medical UniversityTokyoJapan

Personalised recommendations